1. Home
  2. AKRO vs CTRI Comparison

AKRO vs CTRI Comparison

Compare AKRO & CTRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • CTRI
  • Stock Information
  • Founded
  • AKRO 2017
  • CTRI 1909
  • Country
  • AKRO United States
  • CTRI United States
  • Employees
  • AKRO N/A
  • CTRI N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • CTRI
  • Sector
  • AKRO Health Care
  • CTRI
  • Exchange
  • AKRO Nasdaq
  • CTRI Nasdaq
  • Market Cap
  • AKRO 1.8B
  • CTRI 1.8B
  • IPO Year
  • AKRO 2019
  • CTRI 2024
  • Fundamental
  • Price
  • AKRO $51.84
  • CTRI $18.64
  • Analyst Decision
  • AKRO Strong Buy
  • CTRI Hold
  • Analyst Count
  • AKRO 9
  • CTRI 7
  • Target Price
  • AKRO $75.86
  • CTRI $18.83
  • AVG Volume (30 Days)
  • AKRO 2.2M
  • CTRI 476.8K
  • Earning Date
  • AKRO 03-03-2025
  • CTRI 02-26-2025
  • Dividend Yield
  • AKRO N/A
  • CTRI N/A
  • EPS Growth
  • AKRO N/A
  • CTRI N/A
  • EPS
  • AKRO N/A
  • CTRI N/A
  • Revenue
  • AKRO N/A
  • CTRI $2,585,466,000.00
  • Revenue This Year
  • AKRO N/A
  • CTRI N/A
  • Revenue Next Year
  • AKRO N/A
  • CTRI $4.42
  • P/E Ratio
  • AKRO N/A
  • CTRI N/A
  • Revenue Growth
  • AKRO N/A
  • CTRI N/A
  • 52 Week Low
  • AKRO $17.86
  • CTRI $14.47
  • 52 Week High
  • AKRO $58.40
  • CTRI $28.65
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 65.39
  • CTRI N/A
  • Support Level
  • AKRO $48.70
  • CTRI N/A
  • Resistance Level
  • AKRO $51.40
  • CTRI N/A
  • Average True Range (ATR)
  • AKRO 2.29
  • CTRI 0.00
  • MACD
  • AKRO -0.90
  • CTRI 0.00
  • Stochastic Oscillator
  • AKRO 35.50
  • CTRI 0.00

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About CTRI Centuri Holdings Inc. Common Stock

Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings primarily consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. They operate under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.

Share on Social Networks: